What to Expect from Antibody Assays of SARS-CoV-2?
作者信息
Yi Xin, Cao Jing
机构信息
Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX.
Department of Pathology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX.
出版信息
J Appl Lab Med. 2020 Sep 1;5(5):1126-1130. doi: 10.1093/jalm/jfaa100.
Abstract
摘要
相似文献
1
What to Expect from Antibody Assays of SARS-CoV-2?对新型冠状病毒2019（SARS-CoV-2）抗体检测有何期待？
J Appl Lab Med. 2020 Sep 1;5(5):1126-1130. doi: 10.1093/jalm/jfaa100.
2
Serum IgA, IgM, and IgG responses in COVID-19.新冠病毒肺炎中的血清IgA、IgM和IgG反应。
Cell Mol Immunol. 2020 Jul;17(7):773-775. doi: 10.1038/s41423-020-0474-z. Epub 2020 May 28.
3
Serologic testing of coronaviruses from MERS-CoV to SARS-CoV-2: Learning from the past and anticipating the future.从中东呼吸综合征冠状病毒（MERS-CoV）到严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的冠状病毒血清学检测：回顾过去，展望未来。
Travel Med Infect Dis. 2020 Sep-Oct;37:101785. doi: 10.1016/j.tmaid.2020.101785. Epub 2020 Jun 10.
4
Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity.针对 SARS-CoV-2 刺突受体结合域和核衣壳的异源抗体及其对 COVID-19 免疫的影响。
JCI Insight. 2020 Sep 17;5(18):142386. doi: 10.1172/jci.insight.142386.
5
Evaluation of an Electrochemiluminescent SARS-CoV-2 Antibody Assay.一种电化学发光SARS-CoV-2抗体检测方法的评估
J Appl Lab Med. 2020 Nov 1;5(6):1313-1323. doi: 10.1093/jalm/jfaa134.
6
Cross-Comparison of a Chemiluminescent Platform and a Commercial Receptor Binding Domain-Based ELISA for Detecting SARS-CoV-2 IgG.用于检测新型冠状病毒2型免疫球蛋白G的化学发光平台与基于商业受体结合域的酶联免疫吸附测定的交叉比较
J Appl Lab Med. 2020 Nov 1;5(6):1416-1420. doi: 10.1093/jalm/jfaa133.
7
Selecting a SARS-CoV-2/COVID Molecular Testing Method for Your Laboratory.为您的实验室选择一种SARS-CoV-2/新冠病毒分子检测方法。
J Appl Lab Med. 2020 Jul 1;5(4):837-840. doi: 10.1093/jalm/jfaa076.
8
A COVID-19 Patient with Repeatedly Undetectable SARS-CoV-2 Antibodies.一名严重急性呼吸综合征冠状病毒2（SARS-CoV-2）抗体多次检测不到的新型冠状病毒肺炎（COVID-19）患者。
J Appl Lab Med. 2020 Nov 1;5(6):1401-1405. doi: 10.1093/jalm/jfaa137.
9
Serological Assays for SARS-CoV-2 Infectious Disease: Benefits, Limitations and Perspectives.新型冠状病毒2019感染病的血清学检测：益处、局限性与展望
Isr Med Assoc J. 2020 Apr;22(4):203-210.
10
Diagnostic testing for SARS-CoV-2.新型冠状病毒2019（SARS-CoV-2）的诊断检测
CMAJ. 2020 Jun 29;192(26):E713. doi: 10.1503/cmaj.200858. Epub 2020 Jun 3.
引用本文的文献
1
COVID-19 point-of-care tests can identify low-antibody individuals: In-depth immunoanalysis of boosting benefits in a healthy cohort.COVID-19 即时检测可识别低抗体个体：健康队列中增强效益的深入免疫分析。
Sci Adv. 2024 Jun 14;10(24):eadi1379. doi: 10.1126/sciadv.adi1379. Epub 2024 Jun 12.
本文引用的文献
1
Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses.针对 SARS-CoV-2 和其他人类冠状病毒的中和抗体。
Trends Immunol. 2020 May;41(5):355-359. doi: 10.1016/j.it.2020.03.007. Epub 2020 Apr 2.
2
Developing antibody tests for SARS-CoV-2.研发针对新型冠状病毒的抗体检测方法。
Lancet. 2020 Apr 4;395(10230):1101-1102. doi: 10.1016/S0140-6736(20)30788-1.
3
Virological assessment of hospitalized patients with COVID-2019.住院 COVID-19 患者的病毒学评估。
Nature. 2020 May;581(7809):465-469. doi: 10.1038/s41586-020-2196-x. Epub 2020 Apr 1.
4
Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study.SARS-CoV-2 感染后口咽后唾液样本和血清抗体反应中的病毒载量时间特征：一项观察性队列研究。
Lancet Infect Dis. 2020 May;20(5):565-574. doi: 10.1016/S1473-3099(20)30196-1. Epub 2020 Mar 23.
5
Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19).分析早期体液免疫反应以诊断新型冠状病毒病（COVID-19）。
Clin Infect Dis. 2020 Jul 28;71(15):778-785. doi: 10.1093/cid/ciaa310.
Zotero 插件